Extracellular matrix remodeling is necessary for ectopic endometrium implantation. Many studies have shown an increased expression of matrix metalloproteinase 9 (MMP9) in the ectopic endometrium of endometriosis. However, the signaling pathways and cellular effects related to this process remain incompletely elucidated. The objective of our study was to investigate the association between MMP9 and the Wnt signaling pathway under the regulation of 17beta-estradiol (E 2 ) in endometrial stromal cells. We found that MMP9 was elevated in tissues from women with endometriosis compared with normal women. Furthermore, MMP9 and beta-catenin increased concurrently in a time-and dose-dependent manner after E 2 treatment. To clarify the relationship between MMP9 and betacatenin, we performed luciferase promoter reporter and chromatin immunoprecipitation assays. A beta-catenin/TCF3/ LEF1 complex bound to a specific site on the MMP9 promoter that promoted MMP9 gene and protein expression. The promotion of MMP9 by the Wnt signaling pathway under the regulation of E 2 may contribute to the pathophysiology of this disease.
INTRODUCTION
Metastasis, including detachment, invasion, intravasation, extravasation, and implantation, is an intricate process and the main cause of death for most cancers [1] . It is widely accepted that the process of tumor metastasis is controlled by the interaction between the tumor cells and their extracellular environment, including the extracellular matrix (ECM) [2] . In normal conditions, the ECM is regarded as a physical barrier to cell metastasis. However, in tumors, the ECM becomes compromised and more permissive for metastasis due to cleavage of its components by proteases. Matrix metalloproteinases (MMPs) are proteolytic enzymes that are associated with tumor metastasis due to their basic mechanism of action: degradation of various components of the ECM [3] . In recent years, MMPs have been implicated in tumor invasion and metastasis because of their ability to degrade ECM [4, 5] . A decrease in MMP activity inhibits the invasion of tumor cells both in vivo and in vitro [6, 7] .
Although it is considered a benign cancer, endometriosis shares some features with malignant tumors [8, 9] . Endometriosis is defined as endometrial tissues that deposit and grow in sites outside of the uterine cavity. The implantation theory proposed by Sampson in 1927 is widely accepted [10] . For the implantation of endometrium in ectopic locations, breakdown of the ECM is necessary [11] . Thus, we wondered whether MMPs also play vital roles in endometriosis. Recently, considerable interest has focused on MMP9, an important MMP family member. MMP9 degrades type IV collagen, a major component of the basement membrane, and has been implicated in tumor cell invasion and metastasis [12, 13] and in the pathogenesis of endometriosis. Studies have shown that MMP9 is increased in the endometrial tissue of women with endometriosis [14, 15] . MMP9 has been detected at the tissue, mRNA [16] , and protein levels [17] , in an animal model [15] , and even in the urine of patients with endometriosis, making it a strong candidate for the noninvasive diagnosis of endometriosis [18] . While the research conducted to date suggests that MMP9 plays an important role in endometriosis, few studies have elucidated the mechanism underlying the regulation of MMP9, which will be helpful for the understanding and treatment of endometriosis.
Although the pathogenesis of endometriosis is not fully understood, it is well-known that endometriosis is an estrogendependent disease [19] . Therefore, it is interesting to consider that there may be an interaction between estrogen and MMP9. Studies have shown that 17b-estradiol (E 2 ) increases both MMP9 mRNA and MMP9 activity in different tissues or cells [20] [21] [22] . What is more, a recent study has revealed that estrogen can stimulate the expression of MMP9 in endometrial epithelial cells that may play an important role in the pathogenesis of endometriosis [23] . Conversely, other studies have shown that estrogen inhibits MMP9 [24, 25] . So we would like to know whether MMP9 is affected by estrogen in endometriosis, how it is regulated, and what factors are involved.
Several studies have found that the aberrant activation of Wnt/b-catenin signaling may be involved in the pathophysiology of endometriosis [26] [27] [28] . b-Catenin is a multifunctional protein with both structural and signaling roles; it is a subunit of the cell surface cadherin protein complex and can act as an intercellular signal transducer in the Wnt signaling pathway [29] . In this study, we focused on its role in Wnt signaling. In the absence of Wnt ligands, b-catenin is degraded by the APC/ Axin/GSK-3b complex. Binding of Wnt ligands to the Frizzled transmembrane receptors and their LRP coreceptors leads to the inactivation of GSK-3b and accumulation of b-catenin in the cytoplasm. Then, the elevated cytosolic b-catenin can translocate to the nucleus, where it interacts with the TCF/LEF transcription factors, leading to transcriptional activation of Wnt-responsive genes [30] .
Wnt signaling and MMP9 have been extensively studied in a variety of tumors. In colorectal cancer, Lee et al. [31] showed that Wnt3a expression is highly correlated with MMP9 expression. In nasopharyngeal carcinoma tissue, b-catenin and MMP9 expression is dramatically upregulated, and MMP9 expression is suppressed in a time-dependent manner following transfection with b-catenin small interfering RNA (siRNA) [32] . The same regulation of b-catenin on MMP9 was also observed in T-cells [33] . Importantly, the interaction between a nuclear receptor, such as ERa, and Wnt/b-catenin signaling, can result in a diverse array of cellular effects, including altered cellular adhesion, tissue morphogenesis, and oncogenesis. Therefore, we sought to determine if these three factors have cooperating roles in the pathology of endometriosis.
In the present study, we examined ERa, b-catenin, and MMP9 localization and expression in paired eutopic and ectopic endometria of endometriotic patients and in endometria from control patients. We then examined the correlation between b-catenin protein and MMP9 protein levels in the endometrium and the correlation between endometrial bcatenin protein levels and ERa protein levels to determine whether b-catenin was involved in the pathogenesis of endometriosis. We also conducted luciferase experiments and chromatin immunoprecipitation (ChIP) to determine if bcatenin can bind to and activate the MMP9 promoter. Our results provide novel insights into the ability of E 2 to induce MMP9 expression through intracellular Wnt/b-catenin signaling, hence extending the mechanisms through which estrogen triggers endometriosis progression.
MATERIALS AND METHODS

Ethical Approval
Human tissues were obtained in accordance with the guidelines of The Declaration of Helsinki after full and informed patient consent and with the approval by the local Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science.
Patients and Tissues
Patients aged 20-40 yr undergoing laparoscopy for endometriosis were recruited in the Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from 2013 to 2015. The stage of endometriosis was determined according to the revised classification of The American Fertility Society [34] . As control samples, endometrial tissues were curetted from patients with tubal infertility. None of the women had received hormonal treatments, such as gonadotropinreleasing hormone agonists (GnRHa) or sex steroids, and none used intrauterine contraception for at least 6 mo prior to surgery. Recruited patients had regular menstrual cycles (between 26 and 32 days) with confirmation of their menstrual history. At the time of tissue collection, all patients were in the proliferative phase of the menstrual cycle. Thirty-one cases of ovary endometriosis (mean age 27.5 6 5 yr, stages III-IV, 20 cases for Western blot and PCR analyses, 11 cases for immunohistochemistry), 30 cases of eutopic endometrial tissues of endometriosis (mean age 28 6 4 yr, stages III-IV, 20 cases for Western blot and PCR analyses, 10 cases for immunohistochemistry), and 30 cases of normal controls (mean age 26.5 6 6 yr, 20 cases for Western blot and PCR analyses, 10 cases for immunohistochemistry) were recruited. The remaining normal endometrial biopsies were collected under sterile conditions and transported to the laboratory on ice in phosphate-buffered saline (PBS) for stromal cell culture establishment.
Immunohistochemistry
All tissues had been routinely fixed in 4% buffered formaldehyde and processed in paraffin blocks by routine methods. Sections were cut at 5 mm thickness and mounted on coated slides. For immunohistochemical staining, rabbit anti-human ERa (1:50), b-catenin (1:100), and MMP9 (1:50) monoclonal antibodies were used for the avidin-biotin-peroxidase complex procedure. Sections were deparaffinized and rehydrated in graded ethanol, and antigen retrieval was performed in citrate (pH 6.0) for 3 min at full pressure using a pressure cooker. Sections were then treated with 3% hydrogen peroxide for 5 min to inhibit endogenous peroxidase activity. After blocking in 0.01 mol/ L Tris, 0.3% Triton X-100, and 10% normal goat serum for 30 min, sections were incubated overnight at 48C with primary antibody. After rinsing in PBS, sections were incubated with peroxidase-labeled anti-rabbit immunoglobulin G (IgG) for 30 min. Finally, all slides were incubated with 3,3 0 -diaminobenzidine substrate (Beyotime) and counterstained in hematoxylin before they were dehydrated and mounted.
Cell Culture
Studies have shown that endometrial stromal, but not epithelial, cells secrete several MMPs, including MMP9 [35] . Therefore, we isolated endometrial stromal cells (ESCs) from endometrial biopsies performed in the proliferative phase. Briefly, fragments were minced with scissors into 1 mm pieces and enzymatically digested with 0.1% collagenase II (Sigma) for 1 h with agitation at 378C. The digested tissue was filtered through 150 and 37.4 lm sieves to remove debris and glandular epithelial cells, then centrifuged at 1000 rpm for 5 min and suspended in red blood cell lysis buffer (Beyotime) for 10 min to remove red blood cells. After a second centrifugation at 1000 rpm for 5 min, the ESCs at the bottom were resuspended in a 1:1 mixture of phenol redfree Dulbecco minimum essential medium (DMEM)/F12 (Gibco) with 10% fetal bovine serum (FBS) (Gibco) and 1% antibiotics (354352; BD), plated onto 6 cm dishes, and maintained in a humidified 5% CO 2 incubator at 378C. Human endometrial glandular stromal cells (T HESCs) were purchased directly from ATCC (CRL-4003 TM) and maintained in the same kind of medium and environment as the ESCs.
Reagents and Antibodies
17b-Estradiol was purchased from Sigma-Aldrich. Rabbit monoclonal antibodies against b-catenin (8414), TCF3 (2883), LEF1 (2286), as well as horseradish peroxidase-conjugated secondary antibodies were purchased from Cell Signaling Technology. ERa (AF6058) and MMP9 (AF0220) rabbit polyclonal antibody used for immunohistochemistry and Western blot analysis were purchased from Affinity. A MMP9 mouse monoclonal antibody (H00004318-M03) used for dual immunofluorescence was purchased from Abnova.
RNA Extraction and Quantitative Real-Time Reverse Transcription PCR
Total RNA was isolated from the tissues using TRIzol reagent (TAKARA) according to the manufacturer's protocol. Reverse transcription was carried out in the DNA Thermal Cycler 9600 (Perkin-Elmer Corp.) for 15 min at 308C and 5 sec at 858C; quenching was then performed at 48C. After the reaction was completed, samples were stored at À208C until PCR analysis. Amplification for cDNA was performed by using SYBR Premix Ex Tag II (TAKARA) according to the manufacturer's protocol. The melting curve was analyzed following the reactions to check for primer dimer formation and nonspecific product amplification. The 2 À44CT method was employed for the determination of relative transcript abundance.
Western Blot Analysis
Protein isolated from the tissues or culture supernatant from ESCs and T HESCs was subjected to 12% sodium dodecylsulfate-polyacrylamide gel electrophoresis followed by transfer to 0.45 lm polyvinylidene fluoride membranes (Millipore), and the blot was blocked for 1 h at room temperature (RT) with 0.1% TBST (20 mM Tris-HCl, 500 mM NaCl, 0.05% Tween 20, pH 7.5) with added 5% fat-free dried milk powder. The blot was then incubated with primary antibody (1:1000 dilution) at 48C overnight. The blot was washed with 0.1% TBST and incubated with secondary antibody (1:5000 dilution with 5% fat-free dried milk powder in 0.1% TBST) for 1 h. The blot was washed again and then incubated with ECL Western blot detection reagent (Millipore).
Dual Immunofluorescence
ESCs were seeded on glass coverslips placed inside six-well plates and treated with E 2 . The slides were then rinsed once with ice-cold PBS and fixed with 4% paraformaldehyde for 20 min at RT. ESCs were washed with PBS, and permeabilized in PBS containing 0.1% Triton X-100 for 20 min at RT. The ZHANG ET AL. cells were then blocked (5% bovine serum albumin, 1 h, RT) and incubated overnight (48C) with primary antibodies directed against b-catenin (1:100) and MMP9 (1:100). After ESCs were exposed to the primary antibodies, they were incubated with appropriate secondary antibodies conjugated to fluorescein isothiocyanate or Texas Red at RT in a humidified chamber in the dark. 4 0 ,6-Diamidino-2-phenylindole (Sigma), used to stain the nucleus, was incubated for 10 min at RT. The coverslips were then overturned on a microscope slide containing one drop of Prolong Gold anti-fade medium. Immunofluorescently labeled cell monolayers were visualized under an Olympus FV1000 laser scanning confocal microscope (Olympus).
Migration and Invasion Assays
The 8 lm pore size membrane, plain (for migration) or Matrigel-coated (for invasion), polycarbonate filters (Corning Costar) were placed in the wells of 24-well culture plates. After 10 4 /ml ESCs were plated in the top chambers in a low serum medium, the units were transferred to wells containing 500 ml DMEM/F12 medium with 20% FBS as a chemoattractant and incubated at 378C with 5% CO 2 . To assess the migration potential of ESCs, cells were allowed to migrate toward medium over a period of 24 h. In the invasion assays the cells were allowed to invade for 48 h. After removing the cells and Matrigel from the upper surface of the membrane with a cotton bud and staining with 0.1% crystal violet for 15 min, the number of cells on the underside was determined using light microscopy (Olympus). Five randomly selected fields were counted per insert. Duplicate wells were used per condition in each independent experiment.
Chromatin Immunoprecipitation
The T HESCs were cultured to 90% confluence in 150-mm 2 dishes in phenol-red-free Ham nutrient mixture F12 supplemented with 10% FBS, and cotransfections were performed using Lipofectamine 2000 for 48 h. Cells were then incubated with 10 À8 mol/L E 2 or dimethyl sulfoxide as a control for 48 h. ChIP assays were performed using the ChIP Express kit (Millipore) following the manufacturer's protocol. The MMP9 primers were for a 554 bp product corresponding to À596 to À42 bp of the MMP9 gene promoter and were as follows: sense 5 0 -GGAAGATCTGCCCAAGGTCACATAGCT-3 0 and antisense 5 0 -CCCAAGCTTCTCCAGGGAAGAGCACAA-3 0 . Amplification was carried out with a PCR-100 programmable thermal controlled unit (Bio-Rad) after an initial denaturation at 948C for 3 min. This was followed by 34 cycles using the following temperature and time profile: denaturation at 948C for 0.5 min, primer annealing at 608C for 0.5 min, and primer extension at 728C for 40 sec. The PCR products were visualized by electrophoresis on 2% agarose gel in 0.53 TAE buffer (Beyotime).
Dual Luciferase Experiments
The T HESCs were seeded into 24-well plates the night before transfection and cultured to 80%-85% confluence in antibiotic-free and phenol-red-free DMEM/F12 supplemented with 10% FBS. Cells were always cotransfected with the internal control plasmid pRL-SV40 (Promega) containing the Renilla luciferase gene. After the recommended time, E 2 was added into the media for 48 h. Next, cells were washed in PBS, harvested using passive lysis buffer (Promega), and stored at À208C or À808C for short-or long-term storage, respectively. Firefly and Renilla luciferase activities were measured using the dual luciferase assay system kit (Promega).
Statistical Analysis
All data were in normal distribution, and statistical analysis was performed using GraphPad Prism 5; the results were expressed as mean 6 SEM. Single comparisons were performed using the Student t-test. One-way ANOVA followed by the Newman-Keuls test were used to measure comparisons between groups. A P , 0.05 was considered statistically significant. Correlation between b-catenin protein and MMP9 protein levels in ESCs under different concentration and time points of E 2 were examined with the Pearson correlation coefficient.
RESULTS
ERa, b-Catenin, and MMP9 Expression Are Elevated in Endometriotic Patients
As can be seen in Figure 1A , ERa, b-catenin, and MMP9 protein was abundantly expressed in stroma cell of ectopic and eutopic endometria from women with endometriosis compared with normal endometrium. MMP9 protein was almost in the cytoplasm, while ERa and b-catenin protein entered into the nuclear of stroma cell of ectopic and eutopic endometria from women with endometriosis. The results in Figure 1B indicated that compared with the normal eutopic endometrium, both eutopic and ectopic endometrium from the endometriotic patients showed significantly higher ERa, b-catenin, and MMP9 mRNA expression levels throughout (P , 0.05; Fig.  1B) . However, no significant difference in ERa, b-catenin, and MMP9 mRNA expression levels was observed between eutopic and ectopic endometria from the patients with endometriosis (P . 0.05; Fig. 1B) . To analyze ERa, b-catenin, and MMP9 more quantitatively and objectively, we performed Western blot analysis of endometrial sample lysates. Figure 1C shows an example for protein expression of ERa, b-catenin (upper band in the figures is for b-catenin), and MMP9 in normal endometrium and in endometriotic tissues. First, the levels were compared between normal eutopic endometria (labeled normal in the figure) and eutopic endometria with endometriosis (labeled eutopic in the figure). A significant difference was observed between the two groups: ERa increased about 2.6-fold (P ¼ 0.0474), b-catenin increased 2.3-fold (P ¼ 0.0275), and MMP9 increased 6.8-fold (P ¼ 0.0124). Next, normal and ectopic groups were compared. A significant difference was observed between the two groups: ERa increased about 4.8-fold (P ¼ 0.0147), b-catenin increased 4-fold (P ¼ 0.0195), and MMP9 increased 19.7-fold (P ¼ 0.0050). No statistically significant difference was observed upon comparing the eutopic and ectopic groups.
17b-Estradiol Induces MMP9 Expression Through b-Catenin in ESC
To investigate the effect of E 2 on MMP9 activation, ESCs were treated with different concentrations of E 2 (from 10 À12 to 10 À6 mol/L) for 24 h (Figs. 2, A and B, and 3A). As seen in Figure 2A , E 2 enhanced b-catenin and MMP9 expression in ESCs, as determined by Western blots. We further examined the distribution of b-catenin and MMP9 by dual immunofluorescence staining. Our data showed that E 2 increased translocation of b-catenin from the cytoplasm to nuclear (Fig.  3A) . These effects were dose dependent: E 2 induced a significant increase in MMP9 at a concentration of 10 À10 mol/L, and a maximal effect was achieved at 10 À6 mol/L. Because the normal concentration of E 2 in women is about 10 À9 mol/L, we choose 10 À8 mol/L as the pathological condition in our study [36] . To further characterize the effects of E 2 on MMP9 expression in ESC, time-course experiments were carried out in ESCs stimulated with 10 À8 mol/L E 2 (Figs. 2, C and D, and 3B). The presence of E 2 in the culture medium produced an increase in MMP9 expression in the supernatant (Fig. 2, C and D) . The maximal effect was observed at 48 h. The localization of b-catenin showed an increase expression in nuclear in a time-dependent manner (Fig. 3B) . Furthermore, ERa and b-catenin increased coincidently with MMP9 (Fig. 2,  E and F) . To further provide insight into the role of b-catenin in this action, a b-catenin overexpression plasmid (b-cat in Fig.  4A ) and b-catenin siRNA (si-b in Fig. 4A ) were transiently transfected into T HESCs for 48 h and the expression of MMP9 was monitored. MMP9 reached its maximum expression in T HESCs transfected with the b-catenin overexpression plasmid under E 2 conditions, and this effect was blocked by cotransfection with b-catenin siRNA (Fig. 4A) . This phenomenon suggested that Wnt/b-catenin signaling might be activated Wnt PROMOTES MMP9 IN ENDOMETRIOSIS in the presence of E 2 , leading to elevated MMP9 transactivation in T HESCs.
17b-Estradiol Promotes ESCs Migration and Invasion Through b-Catenin
Our results above confirmed the hypothesis that E 2 regulated the expression of MMP9 in a b-catenin-dependent manner. Here, we further studied the migration and invasion ability of THESCs under different conditions. After T HESCs were treated with E 2 or PBS for 48 h, the transwell assay revealed that E 2 led to a significant promotion of cell migration and invasion (Fig. 5A) . We then transfected T HESCs with empty vector (con1) or b-catenin expression plasmids (b-cat). The results showed that b-catenin overexpression led to a significant increase of cell migration and invasion (Fig. 5B) . Furthermore, b-catenin was knocked down by a specific siRNA in T HESCs. As expected, b-catenin knockdown obviously inhibited T HESCs migration and invasion (Fig. 5C) . Thus, the E 2 -induced increase in the migration and invasion of T HESCs was dependent on b-catenin.
MMP9 Promoter Activity Is Induced by b-Catenin
Our initial studies showed that b-catenin stimulation of ESCs increased MMP9 mRNA expression and MMP9 protein release. Previous studies have shown Wnt regulation of MMP9 to occur transcriptionally via distinct and specific transcription factors, depending on cellular context. MMP9 has been shown to be a direct transcriptional target of Wnt signaling in human T-lymphocytes [33] , and previous studies have linked Wnt signaling to endometriosis. To determine the key transcription factor binding sites involved in our system, we used a series of deletions of the MMP9 promoter ranging from À2022 to þ119 bp. We cotransfected T HESCs with the 2022 bp MMP9 reporter and the b-catenin expression construct. This construct strongly activated the MMP9 reporter, confirming that MMP9 genes are transcriptional targets of Wnt/b-catenin signaling in T HESCs. In silico analysis identified four putative TCFbinding sites in the MMP9 proximal promoter (Fig. 6A) . To identify the promoter regions that were responsible for bcatenin function, the 5 0 flanking sequence of the MMP9 promoter was systematically deleted, and each fragment was ligated to the luciferase reporter vector (pGL3-basic), as seen in Figure 6A . A significant increase in b-catenin-mediated luciferase activity was present for all constructs in the deletion series except the P-504 fragment (Fig. 6B) . This suggests that the region between À698 and À386 bp is necessary for bcatenin induction of MMP9. This region corresponds to a region of the MMP9 promoter between 386 to 698 bp upstream of the transcription start site. Then the dual luciferase reporter genes were cotransfected with plasmids expressing b-catenin or an empty vector and b-catenin-specific siRNA or an empty vector. Luciferase activity was measured following incubation with E 2 for 48 h. The results confirmed that MMP9 promoter activity is induced by b-catenin (Fig. 6C) . To provide evidence for a direct requirement for the MMP9 promoter-specific TCF- binding sites, site-directed mutants were created of the TCFbinding site in the MMP9 promoter at À530 bp, using the P-818 bp MMP9 promoter reporter as a template. This construct showed no activation of the MMP9 reporter (Fig. 6D) , confirming the binding site of b-catenin on the MMP9 promoter in T HESCs.
b-Catenin Binds Directly to the MMP9 Promoter
To determine whether b-catenin/TCF3 binds directly to the MMP9 promoter in vivo, we performed ChIP assays with monoclonal antibodies against b-catenin, TCF3, and LEF1. The immunoprecipitated DNA was amplified by using primers specific for a fragment of the MMP9 promoter containing the 
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putative TCF-binding site. Our first set of experiments was designed to determine whether E 2 could influence the binding of the b-catenin/TCF3/LEF1 complex to the MMP9 promoter. Cultured T HESCs were incubated in 10 À8 mol/L E 2 for 48 h in PBS for 48 h as control. 17b-Estradiol induced a significant increase in binding of the b-catenin/TCF3/LEF complex to the MMP9 promoter over IgG antibody control and PBS control (Fig. 7A) . A second set of experiments was designed to demonstrate an in vivo effect of b-catenin on MMP9 promoter function. We transfected T HESCs with the b-catenin overexpression plasmid or b-catenin siRNA, incubated in 10 À8 mol/L E 2 for 48 h, and then performed ChIP analysis. Concomitant and strong b-catenin, TCF3, and LEF1 binding was observed following transfection with the b-catenin overexpression plasmid, while a significant decrease in occupancy by b-catenin, TCF3, and LEF1 at the MMP9 promoter was observed following transfection with b-catenin siRNA (Fig. 7, B and C) . Thus, the b-catenin/TCF3/LEF1 complex may bind directly to the MMP9 promoter, and this interaction can be influenced by E 2 .
DISCUSSION
There are limited data regarding the molecular mechanisms regulating MMP9 expression and activity in endometriosis. The data presented here indicate a central role for b-catenin in the regulation of MMP9 expression by E 2 . Evidence in support of this pathway includes the following: 1) increased expression of ERa, b-catenin, and MMP9 in tissues from patients with endometriosis, 2) treating ESCs with E 2 increased the expression of MMP9 and the resulting b-catenin entered into the nucleus (the b-catenin expression changes coincided with Endometriosis is an invasive but benign disease that affects about 10% of reproductive-aged women. Despite its wellknown symptoms (chronic pelvic pain, dysmenorrhea, dyspareunia, fatigue, and infertility), recent research has shown that endometriosis is associated with a risk of developing several chronic diseases, such as ovarian and breast cancers, ZHANG ET AL. autoimmune diseases, and cardiovascular diseases [37, 38] . Considering this and the frequency of endometriosis, more emphasis has been put on understanding the molecular basis of this important disease in recent years, with the aim of developing more effective prognostic, diagnostic, and/or treatment strategies for the clinical management of this debilitating disease. However, the etiology of endometriosis remains poorly understood and many current clinical treatments are inadequate for symptom relief and have unacceptable side effects [39] .
Several recent studies highlighted the role of MMPs in endometriosis. Although elegant studies have established critical roles for MMP9 in endometrial tissue metastasis, most studies showed only that MMP9 expression increased at the mRNA and protein level, MMP9 activity increased in peritoneal fluid, or tissue inhibitor of metalloproteinase (TIMP) lost activity in ectopic endometrium tissues. However the mechanism of MMP9 upregulation in endometriosis is still unclear. The regulation and function of MMP9 is controlled at multiple levels, including expression, secretion, activation, and localization [40] . In our study, we focused on its expression level. It is interesting to note that MMP9 expression changes coincidentally with b-catenin in coupled eutopic and ectopic endometrial tissues of endometriosis patients compared with normal endometrial tissues. We found that the canonical Wnt signaling pathway promoted the increase in MMP9 mRNA and protein in ESCs to enhance metastasis. Even though the initial research of the Wnt signaling pathway was in developing embryos, it has emerged as a prevalent theme in cancer biology since its discovery three decades ago in mammary and colon cancer. It is not surprising that inhibitors of Wnt/b-catenin signaling are under consideration for treatment of cancers [41, 42] . Herein, we found the important role of Wnt/b-catenin signaling in endometriosis, which may provide new ideas in the treatment of endometriosis.
In the present work, we focused only on MMP9 expression level. In fact, the regulation of MMP9 synthesis and activation is a complex multistep process. In short, the first level is the transcription of the MMP9 gene. Second, specific MMP9 mRNA is synthesized and translated into a latent or pro form of the MMP9 protein. A third level of regulation is the secretion and activation of pro-MMP9. Finally, active MMP9 can be bound with its endogenous inhibitors, such as TIMPs [43] . Whether other factors are involved in this process remains to be further studied. What is more, MMPs are a family of structurally related endopeptidases that play a role in cleaving all components of the ECM [44] . The human endometrium is a remarkable example of cyclic tissue remodeling. Menstrual shedding of large parts of the superficial layer is triggered by a set of MMPs [45] . The endometriotic tissues express higher levels of specific MMPs not only MMP9; for example, MMP1, MMP2, and MMP3 are highly regulated in the endometriotic endometrium [46] [47] [48] [49] . MMP7 expression levels vary significantly among the different forms of endometriosis [50] . Furthermore, MMPs promote tumor progression not only through ECM degradation, as originally thought, but also by affecting multiple signaling pathways that control cell growth, inflammation, or angiogenesis, and may even work in a nonproteolytic manner [51, 52] . Therefore, more studies are needed to determine which cellular or molecular pathways of MMP regulation become altered in association with the disease process of endometriosis.
In summary, we have identified a novel role for Wnt signaling in regulating ESC metastasis. We not only identified a positive correlation between endometrial b-catenin and MMP9 protein levels following E 2 treatment, but also provided evidence for a mechanistic link between b-catenin and MMP9. This is potentially important in understanding the pathogenesis of endometriosis, a complex and persistent disease of the reproductive system, and might provide a novel therapeutic target for this disease.
